ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.
ImmunityBio Inc (NASDAQ:IBRX) shares fell 19% to US$6.97 after the biotechnology company reported a third-quarter revenue shortfall and a sharply wider net loss. The US biopharmaceutical company generated revenue of US$48.84 million in the three months to September 2026, up 52% year on year but...
New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
ImmunityBio, Inc. expands Anktiva's label in bladder cancer, fueling robust sales growth but facing skepticism over pipeline durability. Learn more about IBRX stock here.
ImmunityBio has secured early FDA label expansion for Anktiva in BCG-unresponsive NMIBC. Check out why IBRX stock is a hold.
ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
This is the newest page. Registered accounts read further back.